CTOs on the Move

Tahoe Forest Hospital

www.tfhd.com

 
Proudly serving the community since 1952, Tahoe Forest Hospital is a not for profit rural health care facility and designated Critical Access Hospital. It is fully accredited by the Healthcare Facilities Accreditation Program and licensed by the State of California Department of Health Services. Tahoe Forest Hospital has 25 acute care beds and 36 long-term care beds. Our geographic area covers six rural counties, two states and approximately 3,500 square miles with primary services reaching the communities of Truckee, North Lake Tahoe, Donner Summit and the Sierra Valley in California and Incline Village in Nevada. Tahoe Forest Hospital serves a full-time ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.tfhd.com
  • 10121 Pine Avenue PO Box 759
    Truckee, CA USA 96160
  • Phone: 530.587.6011

Executives

Name Title Contact Details

Similar Companies

Project House

Project House is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TheraNova

TheraNova is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pillo Health

Six in ten Americans live with at least one chronic condition, a leading driver of healthcare costs across the country. Medication non-adherence results in hundreds of billions in wasted costs annually and a higher mortality rate in the U.S. Pillo Health is tackling these issues head-on with an engaging and HIPAA-compliant technology platform dedicated to improving health outcomes for patients at home.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.